|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||91.00 - 91.86|
|52-week range||72.98 - 93.58|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||9.47|
|Forward dividend & yield||3.35 (3.71%)|
|Ex-dividend date||08 Mar 2022|
|1y target est||N/A|
A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.
Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.
The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.